InsidersTradesSigma
Follow the 万孚生物 stock price and the full insider trade history of the company, a publicly traded company based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 万孚生物 has published 7 reports. Market capitalisation: €8bn. The latest transaction was reported on 5 August 2026 (Purchase). Among the most active insiders: 王继华. The full history is accessible without an account.
Analysts rate 万孚生物 Strong Buy (bullish), based on 2 analysts. Average price target: CN¥26.79.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
7 of 7 declarations
万孚生物 is a company focused on the healthcare and pharmaceutical sector, specializing in the development of in vitro diagnostics. It is listed on the XSHE market.